Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Prof Ameenat Solebo
a.solebo@ucl.ac.uk


Prof Ameenat Solebo
a.solebo@ucl.ac.uk


Study Location:

Skip to Main Content

Keep up to date

Sign up for news and information about taking part and shaping research.

English | Cymraeg
Be Part of Research - Trial Details - Pilot study of AS OCT in Paediatric Uveitis

Pilot study of AS OCT in Paediatric Uveitis

Completed

Open to: Female / Male

Age: All

Medical Conditions

Disorders of sclera, cornea, iris and ciliary body


This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.


Paediatric uveitis (inflammation inside the eye) is an uncommon disorder. Affected children are at risk of blindness. In the most common form of the disorder, anterior uveitis, the front chamber of the eye is affected. Inadequate treatment of active disease can result in poorer outcomes. Currently, doctors assess disease activity by looking through a biomicroscope. The number of cells and degree of clouding in the front eye is graded using an internationally agreed scale. This scale has not been validated for use in children, and when used in adults it is open to considerable variability between doctors. OCT, or optical coherence tomography machines, can provide detailed images of the eye. A new adaptation OCT camera may be able to detect and measure inflammation inside the eye. Another new adaptation, OCT angiography, can image blood flow inside the eye. OCT cameras are in common clinical use to assess inflammation in the back of the eye (choroid and retina).

We now propose a pilot study to examine the feasibility of OCT detection of anterior chamber activity, and OCTA classification of disease type, in children. We have undertaken a two-week pilot study, enabled by the loan of an instrument, to begin to understand the acceptability and feasibility of imaging. We now have funds to purchase the necessary instruments. This will allow recruitment of children over a one-year period, which will enable us to undertake the pilot work necessary to perform the analytic validation, ie:
- how best do we use these new cameras in children with uvetis?
- how reliable are the images they take in these children?
The results of the 'analytic validation' will allow us to plan a larger study ('clinical validation') to understand how useful the images are for:
- diagnosing uveitis
- monitoring uveitis
- predicting which treatments will work best
- predicting outcome

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

17 Jun 2018 12 Aug 2020

Observational

Observational type: Validation of investigation /therapeutic procedures;



You can take part if:



You may not be able to take part if:


Corneal pathology Previous history of uveitis or juvenile idiopathic arthritis, or anterior chamber inflammation as determined by slit lamp biomicroscopy, or any corneal opacity


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

Prof Ameenat Solebo
a.solebo@ucl.ac.uk


Prof Ameenat Solebo
a.solebo@ucl.ac.uk



The study is sponsored by University College London and funded by GREAT ORMOND STREET HOSPITAL CHILDREN'S CHARITY; NIHR Academy; .




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details

for Trial ID: CPMS 41839

Last updated 21 October 2022

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.